Ascentage Pharma Group International presented at the J.P. Morgan Healthcare Conference, highlighting achievements in 2025 and outlining the global innovation strategy for 2026. Their dual-engine growth is driven by two core products, Olverembatinib and Lisaftoclax, with strong progress in clinical studies. A next-generation BTK degrader, APG-3288, received IND clearance from the FDA, propelling the expansion of their global innovative pipeline. Multiple global Phase III trials are progressing rapidly, positioning Ascentage Pharma for sustained growth in addressing unmet medical needs in cancer treatment.

Read more at GlobeNewswire: Ascentage Pharma Outlined its Global Innovation Strategy